Popular Articles
Grapefruit Benefits

MedImmune Funds Study To Help Gain Insights Into Full Burden Of RSV Disease Among Premature Infants
MedImmune continues to advance its commitment to pediatric research with today"s announcement of the first observational prospective study designed to assess the burden of respiratory syncytial virus (RSV) among preterm infants 32-to-35 weeks gestational age (GA) in outpatient settings during their first year of life.
generic viagra online
Review Of Brazil's HIV/AIDS Treatment Programs Shows Importance Of Generic Drugs, Researchers Say
"Brazil has been successful in its nearly 20-year effort to treat people living with" HIV/AIDS, and generic medicines have been "a large part of the solution," according to a recent Health Affairs review, UPI reports (UPI, 7/14). The review examines Brazil"s passing of "a law in the 1990s that guaranteed citizens free and universal access to drugs for HIV and AIDS treatment" as well as the country"s production of generic HIV/AIDS medicines in public factories, AHN reports. "The [Brazilian] government also prompted drug companies to lower their prices by threatening to make generic versions of [patented] HIV and AIDS drugs in the public factories," writes AHN (Goodhue, 7/14).
News of the day
Abortion Coverage Likely To Be Next Battle In House Health Reform Legislation
Abortion coverage could become the next "sticking point" in debates over health reform between the House leadership and conservative Democrats, the Los Angeles Times reports. During most of the battle over a health care overhaul, abortion-related issues have taken a "back seat" to clashes between House Energy and Commerce Committee Chair Henry Waxman (D-Calif.) and fiscally conservative Blue Dog Democrats over the cost of the House bill (HR 3200). However, reproductive health issues are increasingly coming into play, with some other conservative Democrats threatening to withdraw support for the bill if coverage of abortion services is not explicitly excluded from receiving federal funding. Rep. Bart Stupak (D-Mich.) and 18 fellow Democrats in June wrote a letter to House Speaker Nancy Pelosi (D-Calif.) stating that they "cannot support any health care proposal unless it excludes abortion from the scope of any government-defined or subsidized health insurance plan." According to the Times, Stupak has "vowed" to press Waxman to include restrictions on abortion coverage in the Energy and Commerce Committee"s version of the House bill. Abortion-rights supporter Rep. Louise Slaughter (D-N.Y.), chair of the House Rules Committee, opposes Stupak"s proposal. Slaughter spokesperson Vincent Morris said, "The starting point for Rep. Slaughter of the health care debate was protecting abortion rights."The Hyde Amendment currently prevents the use of federal Medicaid funds for abortion services. The reach of current law restrictions "grows murkier" if the government forms its own health insurance plan to compete with private insurers or creates a new market that allows the public to choose between various private plans, the Times reports. Both options are under consideration in Congress, and abortion-rights opponents fear that abortion services would be covered unless the language of the bill explicitly forbids it.Abortion-rights supporters argue that the bill would maintain the status quo, as insurance companies already are able to choose whether to cover abortion services. New government restrictions could mean that women seeking abortion coverage would have to choose a more expensive private plan rather than a lower-cost, government-subsidized option, according to abortion-rights advocates. Another concern, they say, is that insurers who currently cover abortion would discontinue that coverage to take advantage of government incentives. In a recent statement, the Planned Parenthood Federation of America said, "Opponents of women"s health and health care reform are exploiting health care reform as a way to push for unprecedented prohibitions on abortion coverage in the private marketplace."The Obama administration is attempting to remain neutral on the issue, the Times reports. White House press secretary Robert Gibbs recently said that "a benefit package is better left to experts in the medical field to determine how best and what procedures to cover." The House bill currently establishes a Health Benefits Advisory Committee to recommend which "essential benefits" should be covered under any government-supported insurance plan. In an interview with CBS News last week, President Obama said that he believes it is "appropriate for us to figure out how to just deliver on the cost savings and not get distracted by the abortion debate."According to the Times, the Obama administration"s silence on the issue is "precisely what worries" antiabortion-rights advocates. Rep. John Fleming (R-La.) said that Obama is "actually making an affirmative statement in favor of" federal funding for abortion services by not taking a stand on the issue (Oliphant, Los Angeles Times, 7/28).
Endocrinology

Comment On Dimebolin (dimebon) Increasing Brain Beta Amyloid In Mouse Models

Dimebolin, originally administered as an antihistamine, has previously been found to help slow the decline of cognitive ability in participants. This study analysed tau and how dimebolin affects build up of the toxic beta amyloid protein, which is widely believed to be linked to the development of dementia. This research showed that while dimebolin had a beneficial effect it actually caused an increase of the beta amyloid in mouse models. "This head scratching research has thrown up surprising results and suggests that while dimebolin provides cognitive benefits it may actually increase levels of toxic beta amyloid in the brain. One possible explanation may be that dimebolin is accelerating the process of beta amyloid development, which may reduce its toxicity. The questions surrounding whether beta amyloid causes nerve death in Alzheimer"s or is a bi-product of the process must be addressed by further research. "One in three people over 65 will die with dementia. Further, more robust research is needed to clarify whether dimebolin is an effective treatment for Alzheimer"s in the long term and if these puzzling increases in beta amyloid are also seen in human brains. With the right investment, dementia can be defeated. Alzheimer"s Society funds research to improve the lives of people today and to find a cure for tomorrow." Professor Clive Ballard Director of Research Alzheimer"s Society Reference: Samuel Gandy, Dimebon regulates amyloid beta metabolism in cultured cells, isolated nerve terminals and interstitial fluid of living rodent brain. Alzheimer"s Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):